The state of Massachusetts currently has 112 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Recruiting
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed/Refractory Non-Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed Classic Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
Recruiting
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Recruiting
The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease, Leukemia, Lymphocytic, Chronic, Lymphoproliferative Disorders
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Recruiting
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Brigham & Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
Recruiting
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which dose of GLPG5101 works best with the least number of side effects. * In the second phase, all participants will get the best dose of the first phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin's B-cell
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Recruiting
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Diffuse Large B-cell Lymphoma
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Recruiting
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Recruiting
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)